Mineralys Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing targeted medicines for the control of hypertension. Our focus lies in addressing diseases driven by abnormally elevated aldosterone. With over 25% of hypertensive patients experiencing elevated aldosterone levels, our goal is to normalize aldosterone levels and provide an effective solution for hypertension control.

Our flagship product, Lorundrostat, is a highly selective aldosterone synthase inhibitor designed specifically to address the underlying cause of hypertension. It has demonstrated impressive clinical results and offers once-daily dosing flexibility, making it convenient for patients. What sets Lorundrostat apart is its selectivity in reducing aldosterone without suppressing cortisol, ensuring a targeted treatment approach.

Controlling hypertension is crucial in reducing the risk of cardiovascular and renal diseases. By offering a more targeted solution for blood pressure management, Mineralys Therapeutics aims to make a positive impact on the lives of millions of hypertensive patients worldwide